MX2010000918A - Derivado de bencimidazol. - Google Patents

Derivado de bencimidazol.

Info

Publication number
MX2010000918A
MX2010000918A MX2010000918A MX2010000918A MX2010000918A MX 2010000918 A MX2010000918 A MX 2010000918A MX 2010000918 A MX2010000918 A MX 2010000918A MX 2010000918 A MX2010000918 A MX 2010000918A MX 2010000918 A MX2010000918 A MX 2010000918A
Authority
MX
Mexico
Prior art keywords
17î2hsd
indole
type
benzimidazole derivative
prostatomegaly
Prior art date
Application number
MX2010000918A
Other languages
English (en)
Inventor
Akio Kamikawa
Masaaki Hirano
Akio Kafefuda
Kentaro Enjo
Takashi Furutani
Yutaka Kondoh
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2010000918A publication Critical patent/MX2010000918A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Se describe un novedoso y excelente método terapéutico y/o profiláctico para tratar prostatomegalia, cáncer de próstata o similares, que se basa en la actividad inhibidora selectiva sobre la 17 ß-HSD de tipo 5. Se encontró que un derivado de indol o de bencimidazol que tiene un grupo fenilo sustituido en el átomo de nitrógeno en un anillo indol o bencimidazol en donde el grupo fenilo tiene un COOH sustituido en él, tiene una actividad inhibidora selectiva potente sobre la 17 ß-HSD de tipo 5, y que el derivado de indol o de bencimidazol se puede usar como un agente profiláctico y/o terapéutico para tratar una enfermedad asociada con la 17 ß-HSD de tipo 5, tal como prostatomegalia, cáncer de próstata o similar, sin ningún efecto segundario adverso inducido por la disminución en el nivel de testosterona.
MX2010000918A 2007-07-24 2008-07-23 Derivado de bencimidazol. MX2010000918A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007192242 2007-07-24
PCT/JP2008/063212 WO2009014150A1 (ja) 2007-07-24 2008-07-23 ベンズイミダゾール誘導体

Publications (1)

Publication Number Publication Date
MX2010000918A true MX2010000918A (es) 2010-03-15

Family

ID=40281399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000918A MX2010000918A (es) 2007-07-24 2008-07-23 Derivado de bencimidazol.

Country Status (8)

Country Link
US (1) US20100190826A1 (es)
EP (1) EP2172454A4 (es)
JP (1) JP5251876B2 (es)
KR (1) KR20100046107A (es)
CN (1) CN101835747A (es)
CA (1) CA2694216A1 (es)
MX (1) MX2010000918A (es)
WO (1) WO2009014150A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012102018A (ja) * 2009-03-03 2012-05-31 Astellas Pharma Inc アミド化合物
EP2768499A4 (en) 2011-10-17 2015-08-26 Univ Vanderbilt INDOMETACIN ANALOGUES FOR THE TREATMENT OF CANCER PROSTATE RESISTANT TO CASTRATION
BR112015000443A2 (pt) 2012-07-10 2017-06-27 Bayer Pharma AG derivados de estra-1,3,5(10),16-tetraeno 3-substituídos, processo para a sua produção, preparações farmacêuticas que contêm os mesmos, bem como seu uso para a produção de medicamentos
CN105008382B (zh) 2013-02-21 2018-01-30 拜耳医药股份公司 用于抑制17β‑羟类固醇脱氢酶(AKR1 C3)的雌甾‑1,3,5(10),16‑四烯‑3‑羧酰胺
WO2018151810A1 (en) * 2017-02-17 2018-08-23 The Scripps Research Institute Defining rna-small molecule affinity landscapes enables design of a small molecular inhibitor of an oncogenic non-coding rna
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1584735A (es) * 1968-03-20 1970-01-02
US3878225A (en) * 1973-03-01 1975-04-15 Hoechst Co American Condensed pyrroles bearing an N-phenyl substituent
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
JPS60224673A (ja) * 1984-04-24 1985-11-09 ヘキスト−ルセル・フア−マシユウテイカルズ・インコ−ポレイテツド １−（アミノアルキルフエニルおよびアミノアルキルベンジル）インド−ルおよびインドリン
CA2077897A1 (en) * 1990-04-13 1991-10-14 Robert G. Franz Substituted benzimidazoles
DK40192D0 (da) 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
AU675484B2 (en) 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
US5698413A (en) * 1993-05-05 1997-12-16 The United States Of America As Represented By The Department Of Health And Human Services Method of evaluating chemotherapeutic agents in vivo
JPH07133224A (ja) 1993-11-10 1995-05-23 Kyowa Hakko Kogyo Co Ltd 動脈硬化治療薬
SK282425B6 (sk) 1995-04-21 2002-01-07 Neurosearch A/S Benzimidazolové zlúčeniny, farmaceutické zmesi obsahujúce tieto zlúčeniny a použitie týchto zlúčenín
GB9605331D0 (en) 1996-03-13 1996-05-15 Glaxo Group Ltd Chemical compounds
DE69739733D1 (de) 1996-10-21 2010-02-25 Neurosearch As 1-phenyl-benzimidazolverbindungen und ihre verwendung als modulatoren des gaba-a-rezeptors
GB9702524D0 (en) 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
CA2323089A1 (en) 1998-03-11 1999-09-16 Endorecherche, Inc. Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use
DE19935219A1 (de) 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
JP2002193947A (ja) 2000-12-26 2002-07-10 Taisho Pharmaceut Co Ltd ベンズイミダゾール誘導体
US7148250B2 (en) * 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
US6989400B2 (en) 2003-01-17 2006-01-24 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia
CN101068781B (zh) * 2004-10-04 2012-02-01 美瑞德生物工程公司 用于阿尔茨海默氏病的化合物
US20070105862A1 (en) 2005-11-10 2007-05-10 Milan Bruncko Heat-shock protein binders
US7855225B2 (en) * 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
GB0614068D0 (en) 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
PE20090720A1 (es) * 2007-05-24 2009-06-11 Wyeth Corp Derivados de azaciclilbenzamida como antagonistas de histamina-3

Also Published As

Publication number Publication date
EP2172454A1 (en) 2010-04-07
US20100190826A1 (en) 2010-07-29
JP5251876B2 (ja) 2013-07-31
CA2694216A1 (en) 2009-01-29
CN101835747A (zh) 2010-09-15
JPWO2009014150A1 (ja) 2010-10-07
EP2172454A4 (en) 2010-12-08
KR20100046107A (ko) 2010-05-06
WO2009014150A1 (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
PH12017500930A1 (en) Hsp90 inhibitor combinations
MX2009009290A (es) Compuestos activos en ppar.
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
ATE533485T1 (de) Cetp-inhibitoren
TW200637522A (en) Skin treatment articles and methods
DK2303044T3 (da) Dragt til rent rum og lignende
PH12013501558A1 (en) New compounds
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
MX2009004047A (es) Compuestos organicos.
MX2010009268A (es) Compuestos que son inhibidores de erk.
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2009013332A (es) Inhibidores de ire-1 alfa.
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
UA102250C2 (ru) Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
MX2010000918A (es) Derivado de bencimidazol.
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
TN2012000092A1 (en) Therapeutic agent for mood disorders
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
IN2012DN03844A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal